Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study).

Trial Profile

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir (Primary) ; Atazanavir/ritonavir; Emtricitabine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms IDEAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 May 2013 NCT reports actual initiation date is 1 Aug 2011.
    • 28 May 2013 Planned End Date changed from 1 Aug 2013 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top